• 
  2023/11/2

  Announcement of the BOD's approval regarding the participation in cash injection of Chuang Yi Biotech Co., Ltd.

• 
  2023/11/2

  TSH Board of Directors Approved Financial Statements For the Nine Months Ended September 30, 2023

• 
  2023/9/6

  TSH Biopharm was invited to attend the institutional investor conference hosted by Concord Securities

• 
  2023/8/14

  TSH Board of Directors Approved Financial Statements For the Six Months Ended June 30, 2023

• 
  2023/7/13

  Expand New Therapeutic Area in Chronic Disease, TSH Entering Ophthalmic Market

• 
  2023/2/24

  TSH Board of Directors resolved to convene the 2023 Annual General Shareholders' Meeting

• 
  2023/3/7

  TSH Biopharm was invited to attend the institutional investor conference hosted by Concord Securities

• 
  2023/5/25

  To announce newly recommended Chairman

• 
  2023/5/25

  ​Important resolutions of the Company's 2023 General Shareholders' Meeting

• 
  2023/5/25

  Announcement of the Ex-dividend Record Date of Cash Dividends